Salvinorin B Ethoxymethyl Ether – High-Purity KOR Agonist for Advanced Research

Salvinorin B Ethoxymethyl Ether (EOM SalB) is a chemically modified analog of Salvinorin A, the primary psychoactive constituent of Salvia divinorum. By introducing an ethoxymethyl group at the C-2 position, EOM SalB exhibits enhanced potency and selectivity towards the kappa-opioid receptor (KOR), distinguishing it from its parent compound. This modification not only increases its receptor affinity but also imparts a G-protein biased signaling profile, which is associated with a reduction in β-arrestin-mediated side effects commonly observed with traditional KOR agonists.

In preclinical studies, EOM SalB has shown promise in promoting remyelination and reducing neuroinflammation, making it a valuable compound for research into multiple sclerosis and other demyelinating disorders. Its unique pharmacodynamic properties offer insights into KOR-mediated pathways and potential therapeutic strategies.

Chemical and Physical Properties

• Chemical Name: Salvinorin B Ethoxymethyl Ether

• Molecular Formula: C₂₃H₂₈O₈

• Molecular Weight: 432.46 g/mol

• Purity: ≥98% (HPLC)

• Appearance: White to off-white crystalline powder

• Solubility: Soluble in DMSO, ethanol, and methanol

• Storage Conditions: Store at -20°C in a dry, dark place

Pharmacology and Mechanism of Action

EOM SalB functions as a potent and selective agonist of the kappa-opioid receptor (KOR). Its G-protein biased signaling profile favors the activation of G-protein pathways over β-arrestin recruitment, which is associated with a reduction in adverse effects such as dysphoria and sedation. This bias enhances its therapeutic potential, particularly in neurological applications.

In vitro assays have demonstrated that EOM SalB exhibits greater potency than Salvinorin A and traditional KOR agonists like U50,488, with a bias factor of 2.53, indicating a strong preference for G-protein signaling pathways. This unique signaling profile contributes to its efficacy in promoting remyelination and reducing neuroinflammation in preclinical models.

Research Applications

• Neuropharmacology: Investigating KOR-mediated signaling pathways and their role in neuroinflammation and neuroprotection.

• Multiple Sclerosis Research: Studying remyelination processes and potential therapeutic interventions for demyelinating diseases.

• Drug Development: Exploring G-protein biased agonists as alternatives to traditional opioids with reduced side effect profiles.

• Receptor Binding Studies: Analyzing ligand-receptor interactions and signaling mechanisms specific to KOR.

Legal Status

As of the latest available information, Salvinorin B Ethoxymethyl Ether is not scheduled under international drug control conventions. However, regulations may vary by country and jurisdiction. Researchers are advised to consult local laws and institutional guidelines before procuring or working with this compound.

Safety and Handling

• Intended Use: For laboratory research purposes only.

• Handling: Use appropriate personal protective equipment (PPE) and conduct all experiments in a certified laboratory setting.

• Disposal: Dispose of waste material in accordance with local, regional, and national regulations.

Disclaimer

This product is intended for research and analytical purposes only. It is not approved for human or veterinary use. Researchers must ensure compliance with all applicable laws and regulations in their respective jurisdictions.